Exhibit



	Three Months Ended												Year Ended
Consumer Self-Care Americas	April 2, 2016			July 2, 2016			October 1, 2016			December 31, 2016			December 31, 2016
Net sales	$	639.1		$	629.9		$	611.2		$	626.8		$	2,507.0
Gross profit	$	202.7		$	227.5		$	205.2		$	215.6		$	851.0
R&D expense	$	18.9		$	18.8		$	18.3		$	18.2		$	74.2
DSG&A expense	$	74.9		$	77.9		$	74.6		$	81.5		$	308.9
Operating income	$	107.3		$	124.4		$	105.0		$	88.9		$	425.6

Selected ratios as a percentage of reported net sales
Gross profit	31.7		%	36.1		%	33.6		%	34.4		%	33.9		%
R&D expense	3.0		%	3.0		%	3.0		%	2.9		%	3.0		%
DSG&A expense	11.7		%	12.4		%	12.2		%	13.0		%	12.3		%
Operating income	16.8		%	19.7		%	17.2		%	14.2		%	17.0		%



	Three Months Ended												Year Ended
Consumer Self-Care International	April 2, 2016			July 2, 2016			October 1, 2016			December 31, 2016			December 31, 2016
Net sales	$	420.1		$	399.5		$	358.3		$	401.9		$	1,579.8
Gross profit	$	192.7		$	182.1		$	148.2		$	145.1		$	668.1
R&D expense	$	10.5		$	10.0		$	10.5		$	9.6		$	40.6
DSG&A expense	$	173.2		$	167.2		$	148.2		$	160.0		$	648.6
Operating income (loss)	$	(398.1	)	$	0.1		$	(1,617.5	)	$	(68.9	)	$	(2,084.4	)

Selected ratios as a percentage of reported net sales
Gross profit	45.9		%	45.6		%	41.4		%	36.1		%	42.3		%
R&D expense	2.5		%	2.5		%	2.9		%	2.4		%	2.6		%
DSG&A expense	41.2		%	41.9		%	41.4		%	39.8		%	41.1		%
Operating income (loss)	(94.8		)%	—		%	(451.5		)%	(17.1		)%	(131.9		)%



	Three Months Ended												Year Ended
Prescription Pharmaceuticals	April 2, 2016			July 2, 2016			October 1, 2016			December 31, 2016			December 31, 2016
Net sales	$	267.5		$	293.3		$	271.0		$	283.4		$	1,115.2
Gross profit	$	127.9		$	129.4		$	121.8		$	121.5		$	500.6
R&D expense	$	14.1		$	16.6		$	19.7		$	12.0		$	62.4
DSG&A expense	$	25.2		$	24.9		$	29.5		$	34.1		$	113.7
Operating income (loss)	$	88.6		$	87.9		$	72.6		$	(269.0	)	$	(19.9	)

Selected ratios as a percentage of reported net sales
Gross profit	47.8		%	44.1		%	44.9		%	42.9		%	44.9		%
R&D expense	5.3		%	5.7		%	7.3		%	4.2		%	5.6		%
DSG&A expense	9.4		%	8.5		%	10.9		%	12.0		%	10.2		%
Operating income (loss)	33.1		%	30.0		%	26.8		%	(94.9		)%	(1.8		)%



	Three Months Ended												Year Ended
Consumer Self-Care Americas	April 1, 2017			July 1, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Net sales	$	582.8		$	604.8		$	598.8		$	643.5		$	2,429.9
Gross profit	$	196.6		$	210.0		$	211.4		$	225.7		$	843.7
R&D expense	$	16.6		$	18.0		$	13.8		$	17.5		$	65.9
DSG&A expense	$	71.4		$	75.7		$	70.4		$	61.6		$	279.1
Operating income	$	83.2		$	110.5		$	129.6		$	147.6		$	470.9

Selected ratios as a percentage of reported net sales
Gross profit	33.7		%	34.7		%	35.3		%	35.1		%	34.7		%
R&D expense	2.8		%	3.0		%	2.3		%	2.7		%	2.7		%
DSG&A expense	12.3		%	12.5		%	11.8		%	9.6		%	11.5		%
Operating income	14.3		%	18.3		%	21.6		%	22.9		%	19.4		%



	Three Months Ended												Year Ended
Consumer Self-Care International	April 1, 2017			July 1, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Net sales	$	354.7		$	356.9		$	343.0		$	351.6		$	1,406.2
Gross profit	$	162.1		$	167.3		$	157.4		$	164.4		$	651.2
R&D expense	$	10.4		$	9.9		$	10.3		$	10.2		$	40.8
DSG&A expense	$	149.3		$	152.2		$	141.5		$	147.9		$	590.9
Operating income (loss)	$	(1.6	)	$	(5.5	)	$	2.0		$	2.4		$	(2.7	)

Selected ratios as a percentage of reported net sales
Gross profit	45.7		%	46.9		%	45.9		%	46.8		%	46.3		%
R&D expense	2.9		%	2.8		%	3.0		%	2.9		%	2.9		%
DSG&A expense	42.1		%	42.6		%	41.3		%	42.1		%	42.0		%
Operating income (loss)	(0.5		)%	(1.5		)%	0.6		%	0.7		%	(0.2		)%



	Three Months Ended												Year Ended
Prescription Pharmaceuticals	April 1, 2017			July 1, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Net sales	$	237.6		$	260.0		$	273.0		$	283.8		$	1,054.4
Gross profit	$	95.5		$	119.6		$	120.0		$	119.5		$	454.6
R&D expense	$	11.1		$	12.7		$	12.4		$	17.9		$	54.1
DSG&A expense	$	21.5		$	11.8		$	22.5		$	35.4		$	91.2
Operating income	$	84.0		$	74.8		$	81.7		$	65.6		$	306.1

Selected ratios as a percentage of reported net sales
Gross profit	40.2		%	46.0		%	44.0		%	42.1		%	43.1		%
R&D expense	4.7		%	4.9		%	4.6		%	6.3		%	5.1		%
DSG&A expense	9.0		%	4.5		%	8.3		%	12.5		%	8.6		%
Operating income	35.4		%	28.8		%	29.9		%	23.1		%	29.0		%



	Three Months Ended												Year Ended
Consumer Self-Care Americas	March 31, 2018			June 30, 2018			September 29, 2018			December 31, 2018			December 31, 2018
Net sales	$	601.6		$	596.9		$	596.2		$	616.9		$	2,411.6
Gross profit	$	205.9		$	202.5		$	189.5		$	191.1		$	789.0
R&D expense	$	15.2		$	66.4		$	13.8		$	15.3		$	110.7
DSG&A expense	$	71.5		$	72.4		$	73.0		$	65.4		$	282.3
Operating income (loss)	$	118.6		$	64.6		$	(119.0	)	$	110.2		$	174.4

Selected ratios as a percentage of reported net sales
Gross profit	34.2		%	33.9		%	31.8		%	31.0		%	32.7		%
R&D expense	2.5		%	11.1		%	2.3		%	2.5		%	4.6		%
DSG&A expense	11.9		%	12.1		%	12.2		%	10.6		%	11.7		%
Operating income (loss)	19.7		%	10.8		%	(20.0		)%	17.9		%	7.2		%



	Three Months Ended												Year Ended
Consumer Self-Care International	March 31, 2018			June 30, 2018			September 29, 2018			December 31, 2018			December 31, 2018
Net sales	$	377.8		$	357.9		$	334.2		$	329.4		$	1,399.3
Gross profit	$	185.9		$	173.2		$	158.6		$	151.0		$	668.7
R&D expense	$	10.6		$	11.2		$	10.3		$	11.8		$	43.9
DSG&A expense	$	162.4		$	156.5		$	134.9		$	145.0		$	598.8
Operating income (loss)	$	12.3		$	4.0		$	(4.7	)	$	(4.8	)	$	6.8

Selected ratios as a percentage of reported net sales
Gross profit	49.2		%	48.4		%	47.5		%	45.8		%	47.8		%
R&D expense	2.8		%	3.1		%	3.1		%	3.6		%	3.1		%
DSG&A expense	43.0		%	43.7		%	40.3		%	44.0		%	42.8		%
Operating income (loss)	3.3		%	1.1		%	(1.4		)%	(1.5		)%	0.5		%



	Three Months Ended												Year Ended
Prescription Pharmaceuticals	March 31, 2018			June 30, 2018			September 29, 2018			December 31, 2018			December 31, 2018
Net sales	$	237.6		$	231.6		$	202.8		$	248.8		$	920.8
Gross profit	$	100.9		$	95.3		$	76.8		$	100.9		$	373.9
R&D expense	$	12.6		$	14.4		$	19.5		$	17.5		$	64.0
DSG&A expense	$	24.1		$	22.6		$	20.7		$	21.1		$	88.5
Operating income	$	61.2		$	53.6		$	36.1		$	63.7		$	214.6

Selected ratios as a percentage of reported net sales
Gross profit	42.5		%	41.1		%	37.9		%	40.6		%	40.6		%
R&D expense	5.3		%	6.2		%	9.6		%	7.0		%	6.9		%
DSG&A expense	10.1		%	9.8		%	10.2		%	8.5		%	9.6		%
Operating income	25.8		%	23.1		%	17.8		%	25.6		%	23.3		%



	Three Months Ended												Year Ended
Consumer Self-Care Americas	April 2, 2016			July 2, 2016			October 1, 2016			December 31, 2016			December 31, 2016
Adjusted net sales	$	592.0		$	587.8		$	590.2		N/A			$	2,396.8
Adjusted gross profit	$	211.3		$	233.8		$	215.2		$	228.2		$	888.5
Adjusted R&D expense	$	18.3		$	18.3		$	18.1		N/A			$	72.9
Adjusted DSG&A expense	$	65.5		$	69.2		$	65.9		$	65.0		$	265.6
Adjusted operating income	$	127.4		$	146.3		$	131.3		$	145.0		$	550.0

Selected ratios as a percentage of adjusted net sales
Adjusted gross profit	35.7		%	39.8		%	36.5		%	36.4		%	37.1		%
Adjusted R&D expense	3.1		%	3.1		%	3.1		%	N/A			3.0		%
Adjusted DSG&A expense	11.1		%	11.8		%	11.2		%	10.4		%	11.1		%
Adjusted operating income	21.5		%	24.9		%	22.2		%	23.1		%	22.9		%



	Three Months Ended												Year Ended
Consumer Self-Care International	April 2, 2016			July 2, 2016			October 1, 2016			December 31, 2016			December 31, 2016
Adjusted net sales	N/A			$	399.4		$	358.1		N/A			$	1,579.5
Adjusted gross profit	$	205.6		$	200.1		$	165.2		$	169.2		$	740.1
Adjusted R&D expense	$	10.3		$	9.8		$	10.1		$	9.5		$	39.7
Adjusted DSG&A expense	$	142.2		$	134.1		$	116.8		$	124.7		$	517.8
Adjusted operating income	$	53.0		$	56.2		$	38.3		$	35.1		$	182.6

Selected ratios as a percentage of adjusted net sales
Adjusted gross profit	48.9		%	50.1		%	46.1		%	42.1		%	46.9		%
Adjusted R&D expense	2.5		%	2.4		%	2.8		%	2.4		%	2.5		%
Adjusted DSG&A expense	33.9		%	33.6		%	32.6		%	31.0		%	32.8		%
Adjusted operating income	12.6		%	14.1		%	10.7		%	8.7		%	11.6		%



	Three Months Ended												Year Ended
Prescription Pharmaceuticals	April 2, 2016			July 2, 2016			October 1, 2016			December 31, 2016			December 31, 2016
Adjusted gross profit	$	153.2		$	155.2		$	148.9		$	149.9		$	607.2
Adjusted DSG&A expense	$	24.9		N/A			$	24.3		$	24.9		$	99.0
Adjusted operating income	$	114.3		$	113.7		$	104.9		$	113.0		$	445.9

Selected ratios as a percentage of reported net sales
Adjusted gross profit	57.3		%	52.9		%	55.0		%	52.9		%	54.5		%
Adjusted DSG&A expense	9.3		%	N/A			9.0		%	8.8		%	8.9		%
Adjusted operating income	42.7		%	38.8		%	38.7		%	39.8		%	40.0		%

⁽¹⁾ See Table I for reconciliation to GAAP numbers



	Three Months Ended												Year Ended
Consumer Self-Care Americas	April 1, 2017			July 1, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Adjusted gross profit	$	209.0		$	222.1		$	223.5		$	237.8		$	892.4
Adjusted DSG&A expense	$	66.6		$	70.9		$	65.6		$	65.3		$	268.4
Adjusted operating income	$	125.7		$	133.3		$	144.1		$	155.0		$	558.1

Selected ratios as a percentage of reported net sales
Adjusted gross profit	35.9		%	36.7		%	37.3		%	37.0		%	36.7		%
Adjusted DSG&A expense	11.4		%	11.7		%	10.9		%	10.1		%	11.0		%
Adjusted operating income	21.6		%	22.0		%	24.1		%	24.1		%	23.0		%



	Three Months Ended												Year Ended
Consumer Self-Care International	April 1, 2017			July 1, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Adjusted gross profit	$	182.4		$	187.8		$	178.9		$	186.1		$	735.2
Adjusted R&D expense	$	10.2		$	9.5		$	10.0		$	9.9		$	39.6
Adjusted DSG&A expense	$	122.8		$	124.4		$	112.0		$	120.8		$	480.0
Adjusted operating income	$	49.5		$	53.8		$	57.0		$	55.4		$	215.7

Selected ratios as a percentage of reported net sales
Adjusted gross profit	51.4		%	52.6		%	52.2		%	52.9		%	52.3		%
Adjusted R&D expense	2.9		%	2.7		%	2.9		%	2.8		%	2.8		%
Adjusted DSG&A expense	34.6		%	34.9		%	32.6		%	34.3		%	34.1		%
Adjusted operating income	13.9		%	15.1		%	16.6		%	15.8		%	15.3		%



	Three Months Ended												Year Ended
Prescription Pharmaceuticals	April 1, 2017			July 1, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Adjusted gross profit	$	117.8		$	142.1		$	141.2		$	141.2		$	542.3
Adjusted DSG&A expense	$	21.4		$	20.5		$	22.4		$	25.7		$	90.0
Adjusted operating income	$	85.3		$	108.9		$	106.3		$	97.6		$	398.1

Selected ratios as a percentage of reported net sales
Adjusted gross profit	49.6		%	54.7		%	51.7		%	49.7		%	51.4		%
Adjusted DSG&A expense	9.0		%	7.9		%	8.2		%	9.1		%	8.5		%
Adjusted operating income	35.9		%	41.9		%	39.0		%	34.4		%	37.8		%

⁽¹⁾ See Table I for reconciliation to GAAP numbers



	Three Months Ended												Year Ended
Consumer Self-Care Americas	March 31, 2018			June 30, 2018			September 29, 2018			December 31, 2018			December 31, 2018
Adjusted gross profit	$	216.4		$	213.1		$	200.1		$	196.6		$	826.2
Adjusted R&D expense	N/A			$	16.4		N/A			N/A			$	60.7
Adjusted DSG&A expense	$	66.8		$	67.6		$	68.3		$	60.7		$	263.4
Adjusted operating income	$	134.3		$	129.0		$	118.0		$	120.7		$	502.0

Selected ratios as a percentage of reported net sales
Adjusted gross profit	36.0		%	35.7		%	33.6		%	31.9		%	34.3		%
Adjusted R&D expense	N/A			2.7		%	N/A			N/A			2.5		%
Adjusted DSG&A expense	11.1		%	11.3		%	11.4		%	9.8		%	10.9		%
Adjusted operating income	22.3		%	21.6		%	19.8		%	19.6		%	20.8		%



	Three Months Ended												Year Ended
Consumer Self-Care International	March 31, 2018			June 30, 2018			September 29, 2018			December 31, 2018			December 31, 2018
Adjusted gross profit	$	208.4		$	195.0		$	179.8		$	171.9		$	755.1
Adjusted R&D expense	$	10.3		$	10.9		$	10.1		$	11.6		$	42.9
Adjusted DSG&A expense	$	132.7		$	128.1		$	105.6		$	117.7		$	484.1
Adjusted operating income	$	65.4		$	55.9		$	64.2		$	42.6		$	228.1

Selected ratios as a percentage of reported net sales
Adjusted gross profit	55.2		%	54.5		%	53.8		%	52.2		%	54.0		%
Adjusted R&D expense	2.7		%	3.0		%	3.0		%	3.5		%	3.1		%
Adjusted DSG&A expense	35.1		%	35.8		%	31.6		%	35.7		%	34.6		%
Adjusted operating income	17.3		%	15.6		%	19.2		%	12.9		%	16.3		%



	Three Months Ended												Year Ended
Prescription Pharmaceuticals	March 31, 2018			June 30, 2018			September 29, 2018			December 31, 2018			December 31, 2018
Adjusted gross profit	$	121.8		$	115.9		$	97.4		$	121.9		$	457.0
Adjusted DSG&A expense	N/A			$	22.4		$	20.6		$	20.9		$	88.0
Adjusted operating income	$	85.1		$	79.1		$	57.4		$	83.4		$	305.0

Selected ratios as a percentage of reported net sales
Adjusted gross profit	51.2		%	50.0		%	48.1		%	49.0		%	49.6		%
Adjusted DSG&A expense	N/A			9.7		%	10.1		%	8.4		%	9.6		%
Adjusted operating income	35.8		%	34.1		%	28.3		%	33.5		%	33.1		%

⁽¹⁾ See Table I for reconciliation to GAAP numbers



Table I
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2016
(in millions)
(unaudited)

	Three Months Ended
	April 2, 2016
Consumer Self-Care Americas	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	639.1		$	202.7		$	18.9		$	74.9		$	107.3
As a % of reported net sales				31.7		%	3.0		%	11.7		%	16.8		%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	12.8		$	—		$	(5.3	)	$	18.1
Operating results attributable to held-for-sale business*	(47.1		)	(7.0		)	(0.6		)	(3.9		)	(2.5		)
Restructuring charges and other termination benefits	—			—			—			—			1.5
Acquisition and integration-related charges and contingent consideration adjustments	—			2.8			—			(0.2		)	3.0
Adjusted	$	592.0		$	211.3		$	18.3		$	65.5		$	127.4
As a % of adjusted net sales				35.7		%	3.1		%	11.1		%	21.5		%

* Held-for-sale business includes U.S. VMS business.
	Three Months Ended
	July 2, 2016
Consumer Self-Care Americas	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	629.9		$	227.5		$	18.8		$	77.9		$	124.4
As a % of reported net sales				36.1		%	3.0		%	12.4		%	19.7		%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	12.4		$	—		$	(5.1	)	$	17.5
Impairment charges	—			—			—			—			6.2
Operating results attributable to held-for-sale business*	(42.1		)	(7.2		)	(0.5		)	(3.7		)	(3.1		)
Restructuring charges and other termination benefits	—			—			—			—			0.3
Acquisition and integration-related charges and contingent consideration adjustments	—			1.1			—			0.1			1.0
Adjusted	$	587.8		$	233.8		$	18.3		$	69.2		$	146.3
As a % of adjusted net sales				39.8		%	3.1		%	11.8		%	24.9		%

* Held-for-sale business includes U.S. VMS business.
	Three Months Ended
	October 1, 2016
Consumer Self-Care Americas	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	611.2		$	205.2		$	18.3		$	74.6		$	105.0
As a % of reported net sales				33.6		%	3.0		%	12.2		%	17.2		%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	12.6		$	—		$	(5.1	)	$	17.7
Impairment charges	—			—			—			—			3.4
Operating results attributable to held-for-sale business*	(21.0		)	(3.4		)	(0.2		)	(3.1		)	(0.1		)
Restructuring charges and other termination benefits	—			—			—			—			4.0
Unusual litigation	—			—			—			—			—
Acquisition and integration-related charges and contingent consideration adjustments	—			0.8			—			(0.5		)	1.3
Adjusted	$	590.2		$	215.2		$	18.1		$	65.9		$	131.3
As a % of adjusted net sales				36.5		%	3.1		%	11.2		%	22.2		%

* Held-for-sale business includes U.S. VMS business.



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2016
(in millions)
(unaudited)

	Three Months Ended
	December 31, 2016
Consumer Self-Care Americas	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	626.8		$	215.6		$	18.2		$	81.5		$	88.9
As a % of reported net sales				34.4		%	2.9		%	13.0		%	14.2		%
Adjustments:
Amortization expense primarily related to acquired intangible assets				$	12.6					$	(5.1	)	$	17.7
Impairment charges				—						—			(0.1		)
Restructuring charges and other termination benefits				—						—			27.1
Unusual litigation				—						(10.2		)	10.2
Acquisition and integration-related charges and contingent consideration adjustments				—						(1.2		)	1.2
Adjusted				$	228.2					$	65.0		$	145.0
As a % of reported net sales				36.4		%				10.4		%	23.1		%

	Year Ended
	December 31, 2016
Consumer Self-Care Americas	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	2,507.0		$	851.0		$	74.2		$	308.9		$	425.6
As a % of reported net sales				33.9		%	3.0		%	12.3		%	17.0		%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	50.4		$	—		$	(20.6	)	$	71.0
Impairment charges	—			—			—			—			9.5
Operating results attributable to held-for-sale business*	(110.2		)	(17.6		)	(1.3		)	(10.7		)	(5.7		)
Restructuring charges and other termination benefits	—			—			—			—			32.9
Unusual litigation	—			—			—			(10.2		)	10.2
Acquisition and integration-related charges and contingent consideration adjustments	—			4.7			—			(1.8		)	6.5
Adjusted	$	2,396.8		$	888.5		$	72.9		$	265.6		$	550.0
As a % of adjusted net sales				37.1		%	3.0		%	11.1		%	22.9		%

* Held-for-sale business includes U.S. VMS business.

	Three Months Ended
	April 2, 2016
Consumer Self-Care International	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	420.1		$	192.7		$	10.5		$	173.2		$	(398.1	)
As a % of reported net sales				45.9		%	2.5		%	41.2		%	(94.8		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets				$	12.9		$	(0.2	)	$	(29.7	)	$	42.8
Impairment charges				—			—			—			403.9
Restructuring charges and other termination benefits				—			—			—			3.1
Acquisition and integration-related charges and contingent consideration adjustments				—			—			(1.3		)	1.3
Adjusted				$	205.6		$	10.3		$	142.2		$	53.0
As a % of reported net sales				48.9		%	2.5		%	33.9		%	12.6		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2016
(in millions)
(unaudited)

	Three Months Ended
	July 2, 2016
Consumer Self-Care International	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	399.5		$	182.1		$	10.0		$	167.2		$	0.1
As a % of reported net sales				45.6		%	2.5		%	41.9		%	—		%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	17.3		$	(0.2	)	$	(29.3	)	$	46.8
Operating results attributable to held-for-sale business*	(0.1		)	0.7			—			(4.0		)	4.7
Restructuring charges and other termination benefits	—			—			—			—			4.8
Acquisition and integration-related charges and contingent consideration adjustments	—			—			—			0.2			(0.2		)
Adjusted	$	399.4		$	200.1		$	9.8		$	134.1		$	56.2
As a % of adjusted net sales				50.1		%	2.4		%	33.6		%	14.1		%

* Held-for-sale business includes the European Sports Brand.

	Three Months Ended
	October 1, 2016
Consumer Self-Care International	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	358.3		$	148.2		$	10.5		$	148.2		$	(1,617.5	)
As a % of reported net sales				41.4		%	2.9		%	41.4		%	(451.5		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	16.9		$	(0.4	)	$	(28.8	)	$	46.1
Impairment charges	—			—			—			—			1,604.5
Operating results attributable to held-for-sale business*	(0.2		)	0.1			—			(2.8		)	2.9
Restructuring charges and other termination benefits	—			—			—			—			2.5
Acquisition and integration-related charges and contingent consideration adjustments	—			—			—			0.2			(0.2		)
Adjusted	$	358.1		$	165.2		$	10.1		$	116.8		$	38.3
As a % of adjusted net sales				46.1		%	2.8		%	32.6		%	10.7		%

* Held-for-sale business includes the European Sports Brand.



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2016
(in millions)
(unaudited)

	Three Months Ended
	December 31, 2016
Consumer Self-Care International	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	401.9		$	145.1		$	9.6		$	160.0		$	(68.9	)
As a % of reported net sales				36.1		%	2.4		%	39.8		%	(17.1		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets				$	20.6		$	(0.1	)	$	(27.5	)	$	48.2
Impairment charges				—			—			—			34.0
Operating results attributable to held-for-sale business*				3.5			—			(6.8		)	10.3
Restructuring charges and other termination benefits				—			—			—			10.5
Acquisition and integration-related charges and contingent consideration adjustments				—			—			(1.0		)	1.0
Adjusted				$	169.2		$	9.5		$	124.7		$	35.1
As a % of reported net sales				42.1		%	2.4		%	31.0		%	8.7		%

* Held-for-sale business includes the European Sports Brand.

	Year Ended
	December 31, 2016
Consumer Self-Care International	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	1,579.8		$	668.1		$	40.6		$	648.6		$	(2,084.4	)
As a % of reported net sales				42.3		%	2.6		%	41.1		%	(131.9		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets	$	—		$	67.7		$	(0.9	)	$	(115.3	)	$	183.9
Impairment charges	—			—			—			—			2,042.4
Operating results attributable to held-for-sale business*	(0.3		)	4.3			—			(13.6		)	17.9
Restructuring charges and other termination benefits	—			—			—			—			20.9
Acquisition and integration-related charges and contingent consideration adjustments	—			—			—			(1.9		)	1.9
Adjusted	$	1,579.5		$	740.1		$	39.7		$	517.8		$	182.6
As a % of adjusted net sales				46.9		%	2.5		%	32.8		%	11.6		%

* Held-for-sale business includes the European Sports Brand.

	Three Months Ended
	April 2, 2016
Prescription Pharmaceuticals	Net Sales			Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	267.5		$	127.9		$	14.1		$	25.2		$	88.6
As a % of reported net sales				47.8		%	5.3		%	9.4		%	33.1		%
Adjustments:
Amortization expense primarily related to acquired intangible assets				$	25.3					$	(0.2	)	$	25.6
Acquisition and integration-related charges and contingent consideration adjustments				—						(0.1		)	0.1
Adjusted				$	153.2					$	24.9		$	114.3
As a % of reported net sales				57.3		%				9.3		%	42.7		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2016
(in millions)
(unaudited)

	Three Months Ended
	July 2, 2016
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	293.3	$	129.4		$	16.6		$	24.9		$	87.9
As a % of reported net sales			44.1		%	5.7		%	8.5		%	30.0		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	25.8								$	25.8
Adjusted			$	155.2								$	113.7
As a % of reported net sales			52.9		%							38.8		%

	Three Months Ended
	October 1, 2016
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	271.0	$	121.8		$	19.7		$	29.5		$	72.6
As a % of reported net sales			44.9		%	7.3		%	10.9		%	26.8		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	27.1					$	(0.2	)	$	27.3
Acquisition and integration-related charges and contingent consideration adjustments			—						(5.0		)	5.0
Adjusted			$	148.9					$	24.3		$	104.9
As a % of reported net sales			55.0		%				9.0		%	38.7		%

	Three Months Ended
	December 31, 2016
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	283.4	$	121.5		$	12.0		$	34.1		$	(269.0	)
As a % of reported net sales			42.9		%	4.2		%	12.0		%	(94.9		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	28.4					$	(0.1	)	$	28.5
Impairment charges			—						—			342.4
Restructuring charges and other termination benefits			—						—			2.0
Unusual litigation			—						(8.2		)	8.2
Acquisition and integration-related charges and contingent consideration adjustments			—						(0.9		)	0.9
Adjusted			$	149.9					$	24.9		$	113.0
As a % of reported net sales			52.9		%				8.8		%	39.8		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2016
(in millions)
(unaudited)

	Year Ended
	December 31, 2016
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	1,115.2	$	500.6		$	62.4		$	113.7		$	(19.9	)
As a % of reported net sales			44.9		%	5.6		%	10.2		%	(1.8		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	106.6					$	(0.5	)	$	107.2
Impairment charges			—						—			342.4
Restructuring charges and other termination benefits			—						—			2.0
Unusual litigation			—						(8.2		)	8.2
Acquisition and integration-related charges and contingent consideration adjustments			—						(6.0		)	6.0
Adjusted			$	607.2					$	99.0		$	445.9
As a % of reported net sales			54.5		%				8.9		%	40.0		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2017
(in millions)
(unaudited)

	Three Months Ended
	April 1, 2017
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	582.8	$	196.6		$	16.6		$	71.4		$	83.2
As a % of reported net sales			33.7		%	2.8		%	12.3		%	14.3		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	12.4					$	(4.8	)	$	17.2
Restructuring charges and other termination benefits			—						—			23.7
Acquisition and integration-related charges and contingent consideration adjustments			—						—			1.6
Adjusted			$	209.0					$	66.6		$	125.7
As a % of reported net sales			35.9		%				11.4		%	21.6		%

	Three Months Ended
	July 1, 2017
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	604.8	$	210.0		$	18.0		$	75.7		$	110.5
As a % of reported net sales			34.7		%	3.0		%	12.5		%	18.3		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	12.1					$	(4.8	)	$	16.9
Impairment charges			—						—			4.1
Restructuring charges and other termination benefits			—						—			4.3
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(2.5		)
Adjusted			$	222.1					$	70.9		$	133.3
As a % of reported net sales			36.7		%				11.7		%	22.0		%

	Three Months Ended
	September 30, 2017
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	598.8	$	211.4		$	13.8		$	70.4		$	129.6
As a % of reported net sales			35.3		%	2.3		%	11.8		%	21.6		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	12.1					$	(4.8	)	$	16.9
Impairment charges			—						—			0.4
Restructuring charges and other termination benefits			—						—			(0.8		)
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(2.0		)
Adjusted			$	223.5					$	65.6		$	144.1
As a % of reported net sales			37.3		%				10.9		%	24.1		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2017
(in millions)
(unaudited)

	Three Months Ended
	December 31, 2017
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	643.5	$	225.7		$	17.5		$	61.6		$	147.6
As a % of reported net sales			35.1		%	2.7		%	9.6		%	22.9		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	12.1					$	(4.8	)	$	16.9
Unusual litigation			—						10.2			(10.2		)
Restructuring charges and other termination benefits			—						—			0.2
Acquisition and integration-related charges and contingent consideration adjustments			—						(1.7		)	0.5
Adjusted			$	237.8					$	65.3		$	155.0
As a % of reported net sales			37.0		%				10.1		%	24.1		%

	Year Ended
	December 31, 2017
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	2,429.9	$	843.7		$	65.9		$	279.1		$	470.9
As a % of reported net sales			34.7		%	2.7		%	11.5		%	19.4		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	48.7					$	(19.2	)	$	67.9
Impairment charges			—						—			4.5
Unusual litigation			—						10.2			(10.2		)
Restructuring charges and other termination benefits			—						—			27.4
Acquisition and integration-related charges and contingent consideration adjustments			—						(1.7		)	(2.4		)
Adjusted			$	892.4					$	268.4		$	558.1
As a % of reported net sales			36.7		%				11.0		%	23.0		%

	Three Months Ended
	April 1, 2017
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	354.7	$	162.1		$	10.4		$	149.3		$	(1.6	)
As a % of reported net sales			45.7		%	2.9		%	42.1		%	(0.5		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	19.8		$	(0.2	)	$	(26.5	)	$	46.6
Impairment charges			—			—			—			1.1
Operating results attributable to held-for-sale business*			0.5			—			—			0.5
Restructuring charges and other termination benefits			—			—			—			2.9
Adjusted			$	182.4		$	10.2		$	122.8		$	49.5
As a % of reported net sales			51.4		%	2.9		%	34.6		%	13.9		%

* Held-for-sale business includes the European Sports Brand.



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2017
(in millions)
(unaudited)

	Three Months Ended
	July 1, 2017
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	356.9	$	167.3		$	9.9		$	152.2		$	(5.5	)
As a % of reported net sales			46.9		%	2.8		%	42.6		%	(1.5		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	20.5		$	(0.4	)	$	(27.8	)	$	48.6
Impairment charges			—			—			—			3.7
Restructuring charges and other termination benefits			—			—			—			6.4
Acquisition and integration-related charges and contingent consideration adjustments			—			—			—			0.6
Adjusted			$	187.8		$	9.5		$	124.4		$	53.8
As a % of reported net sales			52.6		%	2.7		%	34.9		%	15.1		%

	Three Months Ended
	September 30, 2017
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	343.0	$	157.4		$	10.3		$	141.5		$	2.0
As a % of reported net sales			45.9		%	3.0		%	41.3		%	0.6		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.5		$	(0.3	)	$	(29.5	)	$	51.5
Restructuring charges and other termination benefits			—			—			—			3.5
Adjusted			$	178.9		$	10.0		$	112.0		$	57.0
As a % of reported net sales			52.2		%	2.9		%	32.6		%	16.6		%

	Three Months Ended
	December 31, 2017
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	351.6	$	164.4		$	10.2		$	147.9		$	2.4
As a % of reported net sales			46.8		%	2.9		%	42.1		%	0.7		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.7		$	(0.3	)	$	(29.5	)	$	51.4
Restructuring charges and other termination benefits			—			—			—			3.6
Acquisition and integration-related charges and contingent consideration adjustments			—			—			2.4			(2.0		)
Adjusted			$	186.1		$	9.9		$	120.8		$	55.4
As a % of reported net sales			52.9		%	2.8		%	34.3		%	15.8		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2017
(in millions)
(unaudited)

	Year Ended
	December 31, 2017
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	1,406.2	$	651.2		$	40.8		$	590.9		$	(2.7	)
As a % of reported net sales			46.3		%	2.9		%	42.0		%	(0.2		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	83.5		$	(1.2	)	$	(113.3	)	$	198.1
Impairment charges			—			—			—			4.8
Operating results attributable to held-for-sale business*			0.5			—			—			0.5
Restructuring charges and other termination benefits			—			—			—			16.4
Acquisition and integration-related charges and contingent consideration adjustments			—			—			2.4			(1.4		)
Adjusted			$	735.2		$	39.6		$	480.0		$	215.7
As a % of reported net sales			52.3		%	2.8		%	34.1		%	15.3		%

* Held-for-sale business includes the European Sports Brand.



	Three Months Ended
	April 1, 2017
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	237.6	$	95.5		$	11.1		$	21.5		$	84.0
As a % of reported net sales			40.2		%	4.7		%	9.0		%	35.4		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	22.4					$	(0.1	)	$	22.6
Impairment charges			—						—			11.1
Gain/loss on divestitures			—						—			(21.8		)
Restructuring charges and other termination benefits			—						—			5.6
Operating results attributable to held-for-sale business			(0.1		)				—			(0.1		)
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(16.1		)
Adjusted			$	117.8					$	21.4		$	85.3
As a % of reported net sales			49.6		%				9.0		%	35.9		%

	Three Months Ended
	July 1, 2017
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	260.0	$	119.6		$	12.7		$	11.8		$	74.8
As a % of reported net sales			46.0		%	4.9		%	4.5		%	28.8		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	22.5					$	(0.1	)	$	22.6
Unusual litigation			—						8.8			(8.8		)
Impairment charges			—						—			19.6
Gain/loss on divestitures			—						—			(1.1		)
Restructuring charges and other termination benefits			—						—			0.4
Acquisition and integration-related charges and contingent consideration adjustments			—						—			1.4
Adjusted			$	142.1					$	20.5		$	108.9
As a % of reported net sales			54.7		%				7.9		%	41.9		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2017
(in millions)
(unaudited)

	Three Months Ended
	September 30, 2017
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	273.0	$	120.0		$	12.4		$	22.5		$	81.7
As a % of reported net sales			44.0		%	4.6		%	8.3		%	29.9		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.2					$	(0.1	)	$	21.3
Impairment charges			—						—			4.0
Restructuring charges and other termination benefits			—						—			0.2
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(0.9		)
Adjusted			$	141.2					$	22.4		$	106.3
As a % of reported net sales			51.7		%				8.2		%	39.0		%

	Three Months Ended
	December 31, 2017
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	283.8	$	119.5		$	17.9		$	35.4		$	65.6
As a % of reported net sales			42.1		%	6.3		%	12.5		%	23.1		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.7					$	0.3		$	21.3
Unusual litigation			—						(10.0		)	10.0
Impairment charges			—						—			0.1
Gain/loss on divestitures			—						—			(0.3		)
Restructuring charges and other termination benefits			—						—			0.2
Acquisition and integration-related charges and contingent consideration adjustments			—						—			0.7
Adjusted			$	141.2					$	25.7		$	97.6
As a % of reported net sales			49.7		%				9.1		%	34.4		%

	Year Ended
	December 31, 2017
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	1,054.4	$	454.6		$	54.1		$	91.2		$	306.1
As a % of reported net sales			43.1		%	5.1		%	8.6		%	29.0		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	87.8					$	—		$	87.8
Unusual litigation			—						(1.2		)	1.2
Impairment charges			—						—			34.8
Gain/loss on divestitures			—						—			(23.2		)
Restructuring charges and other termination benefits			—						—			6.4
Operating results attributable to held-for-sale business			(0.1		)				—			(0.1		)
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(14.9		)
Adjusted			$	542.3					$	90.0		$	398.1
As a % of reported net sales			51.4		%				8.5		%	37.8		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2018
(in millions)
(unaudited)

	Three Months Ended
	March 31, 2018
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	601.6	$	205.9		$	15.2		$	71.5		$	118.6
As a % of reported net sales			34.2		%	2.5		%	11.9		%	19.7		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	10.5					$	(4.7	)	$	15.2
Restructuring charges and other termination benefits			—						—			0.4
Acquisition and integration-related charges and contingent consideration adjustments			—						—			0.1
Adjusted			$	216.4					$	66.8		$	134.3
As a % of reported net sales			36.0		%				11.1		%	22.3		%

	Three Months Ended
	June 30, 2018
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	596.9	$	202.5		$	66.4		$	72.4		$	64.6
As a % of reported net sales			33.9		%	11.1		%	12.1		%	10.8		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	10.6		$	—		$	(4.8	)	$	15.3
Impairment charges			—			—			—			0.6
Acquisition and integration-related charges and contingent consideration adjustments			—			(50.0		)	—			48.5
Adjusted			$	213.1		$	16.4		$	67.6		$	129.0
As a % of reported net sales			35.7		%	2.7		%	11.3		%	21.6		%

	Three Months Ended
	September 29, 2018
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	596.2	$	189.5		$	13.8		$	73.0		$	(119.0	)
As a % of reported net sales			31.8		%	2.3		%	12.2		%	(20.0		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	10.6					$	(4.7	)	$	15.3
Impairment charges			—						—			221.7
Adjusted			$	200.1					$	68.3		$	118.0
As a % of reported net sales			33.6		%				11.4		%	19.8		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2018
(in millions)
(unaudited)

	Three Months Ended
	December 31, 2018
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	616.9	$	191.1		$	15.3		$	65.4		$	110.2
As a % of reported net sales			31.0		%	2.5		%	10.6		%	17.9		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	5.5					$	(4.7	)	$	10.2
Impairment charges			—						—			0.3
Adjusted			$	196.6					$	60.7		$	120.7
As a % of adjusted net sales			31.9		%				9.8		%	19.6		%

	Year Ended
	December 31, 2018
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	2,411.6	$	789.0		$	110.7		$	282.3		$	174.4
As a % of reported net sales			32.7		%	4.6		%	11.7		%	7.2		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	37.2		$	—		$	(18.9	)	$	56.0
Impairment charges			—			—			—			222.6
Restructuring charges and other termination benefits			—			—			—			0.4
Acquisition and integration-related charges and contingent consideration adjustments			—			(50.0		)	—			48.6
Adjusted			$	826.2		$	60.7		$	263.4		$	502.0
As a % of reported net sales			34.3		%	2.5		%	10.9		%	20.8		%

	Three Months Ended
	March 31, 2018
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	377.8	$	185.9		$	10.6		$	162.4		$	12.3
As a % of reported net sales			49.2		%	2.8		%	43.0		%	3.3		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	22.5		$	(0.3	)	$	(29.7	)	$	52.5
Restructuring charges and other termination benefits			—			—			—			0.6
Adjusted			$	208.4		$	10.3		$	132.7		$	65.4
As a % of reported net sales			55.2		%	2.7		%	35.1		%	17.3		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2018
(in millions)
(unaudited)

	Three Months Ended
	June 30, 2018
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	357.9	$	173.2		$	11.2		$	156.5		$	4.0
As a % of reported net sales			48.4		%	3.1		%	43.7		%	1.1		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.8		$	(0.3	)	$	(28.4	)	$	50.4
Impairment charges			—			—			—			1.0
Restructuring charges and other termination benefits			—			—			—			0.5
Adjusted			$	195.0		$	10.9		$	128.1		$	55.9
As a % of reported net sales			54.5		%	3.0		%	35.8		%	15.6		%

	Three Months Ended
	September 29, 2018
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	334.2	$	158.6		$	10.3		$	134.9		$	(4.7	)
As a % of reported net sales			47.5		%	3.1		%	40.3		%	(1.4		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.2		$	(0.2	)	$	(27.9	)	$	49.4
Impairment charges			—			—			—			0.1
Unusual litigation			—			—			(1.4		)	1.4
Restructuring charges and other termination benefits			—			—			—			18.0
Adjusted			$	179.8		$	10.1		$	105.6		$	64.2
As a % of reported net sales			53.8		%	3.0		%	31.6		%	19.2		%

	Three Months Ended
	December 31, 2018
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income (Loss)
Reported	$	329.4	$	151.0		$	11.8		$	145.0		$	(4.8	)
As a % of reported net sales			45.8		%	3.6		%	44.0		%	(1.5		)%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	20.9		$	(0.2	)	$	(25.5	)	$	46.6
Impairment charges			—			—			—			0.7
Unusual litigation			—			—			(1.8		)	1.8
Restructuring charges and other termination benefits			—			—			—			(1.7		)
Adjusted			$	171.9		$	11.6		$	117.7		$	42.6
As a % of reported net sales			52.2		%	3.5		%	35.7		%	12.9		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2018
(in millions)
(unaudited)

	Year Ended
	December 31, 2018
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	1,399.3	$	668.7		$	43.9		$	598.8		$	6.8
As a % of reported net sales			47.8		%	3.1		%	42.8		%	0.5		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	86.4		$	(1.0	)	$	(111.5	)	$	198.9
Impairment charges			—			—			—			1.8
Unusual litigation			—			—			(3.2		)	3.2
Restructuring charges and other termination benefits			—			—			—			17.4
Adjusted			$	755.1		$	42.9		$	484.1		$	228.1
As a % of reported net sales			54.0		%	3.1		%	34.6		%	16.3		%

	Three Months Ended
	March 31, 2018
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	237.6	$	100.9		$	12.6		$	24.1		$	61.2
As a % of reported net sales			42.5		%	5.3		%	10.1		%	25.8		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	20.9								$	20.9
Gain/loss on divestitures			—									(1.2		)
Restructuring charges and other termination benefits			—									0.2
Acquisition and integration-related charges and contingent consideration adjustments			—									4.0
Adjusted			$	121.8								$	85.1
As a % of reported net sales			51.2		%							35.8		%

	Three Months Ended
	June 30, 2018
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	231.6	$	95.3		$	14.4		$	22.6		$	53.6
As a % of reported net sales			41.1		%	6.2		%	9.8		%	23.1		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	20.6					$	(0.2	)	$	20.8
Acquisition and integration-related charges and contingent consideration adjustments			$	—					$	—		$	4.7
Adjusted			$	115.9					$	22.4		$	79.1
As a % of reported net sales			50.0		%				9.7		%	34.1		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
QUARTERS AND FISCAL YEAR 2018
(in millions)
(unaudited)

	Three Months Ended
	September 29, 2018
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	202.8	$	76.8		$	19.5		$	20.7		$	36.1
As a % of reported net sales			37.9		%	9.6		%	10.2		%	17.8		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	20.6					$	(0.1	)	$	20.8
Acquisition and integration-related charges and contingent consideration adjustments			—						—			0.5
Adjusted			$	97.4					$	20.6		$	57.4
As a % of reported net sales			48.1		%				10.1		%	28.3		%

	Three Months Ended
	December 31, 2018
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	248.8	$	100.9		$	17.5		$	21.1		$	63.7
As a % of reported net sales			40.6		%	7.0		%	8.5		%	25.6		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	21.0					$	(0.2	)	$	21.1
Gain/loss on divestitures			—						—			(0.2		)
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(1.2		)
Adjusted			$	121.9					$	20.9		$	83.4
As a % of reported net sales			49.0		%				8.4		%	33.5		%

	Year Ended
	December 31, 2018
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	920.8	$	373.9		$	64.0		$	88.5		$	214.6
As a % of reported net sales			40.6		%	6.9		%	9.6		%	23.3		%
Adjustments:
Amortization expense primarily related to acquired intangible assets			$	83.1					$	(0.5	)	$	83.6
Gain/loss on divestitures			—						—			(1.4		)
Restructuring charges and other termination benefits			—						—			0.2
Acquisition and integration-related charges and contingent consideration adjustments			—						—			8.0
Adjusted			$	457.0					$	88.0		$	305.0
As a % of reported net sales			49.6		%				9.6		%	33.1		%



Table I (continued)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
FIRST QUARTER 2019
(in millions)
(unaudited)

	Three Months Ended
	March 30, 2019
Consumer Self-Care Americas	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	581.8	$	184.0		$	15.6		$	73.3		$	94.2
As a % of reported net sales			31.6		%	2.7		%	12.6		%	16.2		%
Adjustments:
Amortization expense related primarily to acquired intangible assets			$	5.4					$	(4.7	)	$	10.1
Unusual litigation			—						(1.2		)	1.2
Impairment charges			—						—			4.1
Restructuring charges and other termination benefits			—						—			0.8
Acquisition and integration-related charges and contingent consideration adjustments			—						—			(4.1		)
Adjusted			$	189.4					$	67.4		$	106.3
As a % of reported net sales			32.5		%				11.6		%	18.3		%



	Three Months Ended
	March 30, 2019
Consumer Self-Care International	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	350.8	$	168.4		$	10.3		$	149.4		$	8.1
As a % of reported net sales			48.0		%	2.9		%	42.6		%	2.3		%
Adjustments:
Amortization expense related primarily to acquired intangible assets			$	20.8		$	(0.1	)	$	(24.2	)	$	45.1
Restructuring charges and other termination benefits			—			—			—			0.6
Unusual litigation			—			—			(0.3		)	0.3
Adjusted			$	189.2		$	10.2		$	124.9		$	54.1
As a % of reported net sales			53.9		%	2.9		%	35.6		%	15.4		%



	Three Months Ended
	March 30, 2019
Prescription Pharmaceuticals	Net Sales		Gross Profit			R&D Expense			DSG&A Expense			Operating Income
Reported	$	241.9	$	96.4		$	14.3		$	21.6		$	60.6
As a % of reported net sales			39.9		%	5.9		%	8.9		%	25.1		%
Adjustments:
Amortization expense related primarily to acquired intangible assets			$	21.2					$	(0.1	)	$	21.3
Gain/loss on divestitures			—						—			(1.3		)
Acquisition and integration-related charges and contingent consideration adjustments			—						—			1.3
Adjusted			$	117.6					$	21.5		$	81.9
As a % of reported net sales			48.6		%				8.9		%	33.9		%



	Three Months Ended
Consumer Self-Care Americas	March 30, 2019
Net sales	$	581.8
Gross profit	$	184.0
R&D expense	$	15.6
DSG&A expense	$	73.3
Operating income	$	94.2

Selected ratios as a percentage of reported net sales
Gross profit	31.6		%
R&D expense	2.7		%
DSG&A expense	12.6		%
Operating income	16.2		%